Results from Episealer® Knee multicentre study submitted

Episurf Medical (NASDAQ: EPISB) today announces that the company has been informed by the authors about the submission to a scientific journal of the manuscript “Patient-specific metal implants for focal chondral and osteochondral lesions in the knee – Excellent clinical results at 2 years”. This manuscript covers results from a European multicentre study of the Episealer® Knee implant with 75 patients.

“This is wonderful news, and we are incredibly happy. We are now looking forward to seeing this paper published. The size of the study is several times larger than anything previously published on the Episealer®, and this is undoubtedly a large study”, says Pål Ryfors, CEO Episurf Medical.

For more information, please contact:

Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.

Tags: